Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rha, S. Y.
Right arrow Articles by Von Hoff, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rha, S. Y.
Right arrow Articles by Von Hoff, D.
Clinical Cancer Research Vol. 6, 987-993, March 2000
© 2000 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Effect of Telomere and Telomerase Interactive Agents on Human Tumor and Normal Cell Lines1

Sun Young Rha2, Elzbieta Izbicka, Richard Lawrence, Karen Davidson, Daekyu Sun, Mary Pat Moyer, G. David Roodman, Lawrence Hurley and Daniel Von Hoff

Cancer Therapy & Research Center, Institute for Drug Development [S. Y. R., E. I., R. L., K. D., D. S., D. V. H.], Department of Surgery [M. P. M.], and Department of Medicine, Division of Hematology [G. D. R.], The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229; Institute for Cellular and Molecular Biology, Division of Medicinal Chemistry and Drug Dynamics Institute, The University of Texas at Austin, Austin, Texas 78712 [L. H.]; and INCELL Corporation, San Antonio, Texas 78249 [M. P. M.]

Shortening of telomeres along with an up-regulation of telomerase is implicated in the immortality of tumor cells. Targeting either telomeres or telomerase with specific compounds has been proposed as an anticancer strategy. Because telomerase activity and telomeres are found in normal cells, telomere or telomerase targeting agents could induce side effects in normal tissues. We evaluated the effects of telomere and telomerase interactive agents in human tumor and normal cell lines to try to determine the potential side effects those agents might induce in patients. Toxicity of the G-quadruplex interactive porphyrins (TMPyP4, TMPyP2) and azidothymidine (AZT) were tested using a cell-counting technique against normal human cell lines (CRL-2115 and CRL-2120, fibroblasts; NHEK-Ad, adult keratinocytes; CCL-241, small intestinal cells; NCM 460, colonic mucosal epithelial cells) and human tumor cell lines (MDA-MB 231 and Hs 578T, breast cancer; SK-N-FI, neuroblastoma; HeLa, cervix cancer; MIA PaCa-2, pancreatic cancer; HT-29 and HCT-116, colon cancer; DU 145, prostatic cancer cell line). Telomerase activity of these cell lines was measured by a non-PCR-based conventional assay. The effects of TMPyP2, TMPyP4, and AZT were also evaluated against normal human bone marrow specimens, using a granulocyte-macrophage colony-forming assay (CFU-GM). AZT showed very low cytotoxic effects against normal and tumor cell lines, with the IC50 values above 200 µM. The IC50 values for TMPyP2 and TMPyP4 in normal human cell lines were in the range of 2.9–48.3 µM and 1.7–15.5 µM, respectively, whereas in tumor cell lines the IC50 values were 11.4–53 µM and 9.0–28.2 µM, respectively. Within the tissue types, keratinocytes were more sensitive to TMPyP4 than fibroblasts, and small intestinal cells were more sensitive than colonic mucosal epithelial cells. The IC50 for TMPyP2 and TMPyP4 in the normal marrow colony-forming assays were 19.3 ± 5.1 µM and 47.9 ± 1.0 µM, respectively. In conclusion, the in vitro cytotoxicity of the telomere interactive agent TMPyP4 is comparable in human tumor and normal cell lines, which indicates that TMPyP4 could have effects on normal tissues.




This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
M. V. Stankov, R. E. Schmidt, G. M. N. Behrens, and for the German Competence Network HIV/AIDS
Zidovudine Impairs Adipogenic Differentiation through Inhibition of Clonal Expansion
Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2882 - 2889.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Kondo, N. Oue, K. Yoshida, Y. Mitani, K. Naka, H. Nakayama, and W. Yasui
Expression of POT1 is Associated with Tumor Stage and Telomere Length in Gastric Carcinoma
Cancer Res., January 15, 2004; 64(2): 523 - 529.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.